4th Tumor Myeloid Targeting Therapies Summit 2024
June 11 - 13, 2024 - MA USHanson Wade
info@hansonwade.com
Phone:+1 617 455 4188
The landscape of innate immune cells is rapidly advancing towards clinical applications. Multiple published studies in the last year repeatedly affirm that targeting myeloid cells rather than the cancer cells themselves can shrink tumors, further providing confidence in their potential as a clinically effective therapeutic. The 4th Annual Tumor Myeloid Targeting Therapies Summit captures this progressive momentum and is welcoming innate immunity experts from biopharma and academia to showcase novel clinical practices across multiple myeloid subsets. As the field extends beyond macrophages, this meeting will also cover MDSCs, neutrophils and dendritic cells and delves into their intricate interactions within the TME for treating resistance in a range of cancers. Hear from the likes of MD Anderson, Gilead Sciences, Onchilles Pharma, DEM Biopharma, NGM Biopharma and many more to uncover translational lessons learned when using combination therapies for tumor eradication, discover novel targets to assess the efficacy of myeloid cell-based interventions, decipher the complexities of the TME in liquid and solid tumors and more in this year's agenda. As we stand at the forefront of ground-breaking discoveries, prioritizing collaboration becomes essential to unveil the most effective myeloid-based therapies while addressing key challenges that stand in the way of their development. Join your peers in the innate immunity field to take part in strategic networking and scientific knowledge exchange at this must-attend event. Time: 8:00 AM - 5:00 PM